MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from shares sold
for cash
$3,474,051
Net cash provided by
financing activities
$3,474,051
Net change in cash
for the period
$2,479,110
Canceled cashflow
$994,941
Accounts receivable
-$280,314
Prepaid expenses and
deposits
-$256,919
Stock based
compensation
$74,895
Unrealized loss on
marketable securities
-$22,093
Depreciation and
amortization
$16,866
Noncash lease expense
$7,331
Lease accretion
$1,937
Net cash used in
operating activities
-$984,098
Effect of exchange rate
changes on cash
-$5,744
Net cash used in
investing activities
-$5,099
Canceled cashflow
$660,355
Net loss
$1,597,503
Additions to intellectual
property
$5,099
Accounts payable and
accrued liabilities
-$37,613
Operating lease liability
-$9,337
Back
Back
Cash Flow
source: myfinsight.com
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)